Gilde Healthcare
Gilde Healthcare Partners B.V. is a private equity and venture capital firm based in Utrecht, Netherlands, with additional offices in Cambridge, Massachusetts, and Frankfurt am Main, Germany. Established in 2000, the firm specializes in investing in the healthcare sector, focusing on healthcare technology, medtech, diagnostics, digital health, therapeutics, and healthcare services. Gilde Healthcare targets lower mid-market companies and seeks to lead investments, typically investing between €1 million and €35 million in firms with enterprise values up to €150 million. The firm emphasizes sectors such as biopharma, medical devices, clinical decision support, and various healthcare services, including primary and specialized care. Gilde Healthcare aims to take both majority and minority stakes in its portfolio companies and actively participates in their management by securing board positions. The firm primarily invests in the United States and Europe, particularly in the Benelux region.
Tagworks Pharmaceuticals
Series A in 2023
Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands. Tagworks develops In vivo chemistry to improve the efficacy of cancer therapies and to enable novel approaches in companion diagnostics. The company’s facilities are located at the Radboud University Medical Center in Nijmegen. Founded in 2011, Tagworks is a spin-out of Philips Healthcare, and originates from Philips’ molecular imaging expertise.
Lava Therapeutics
Series C in 2020
Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.
AM Pharma
Venture Round in 2020
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.
AM Pharma
Series F in 2019
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.
Lava Therapeutics
Series A in 2018
Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.
NIZO
Private Equity Round in 2016
NIZO food research is a leading global center in proteins, bacteria, and processing. They are an independent company and one of the most advanced contract research centers in the world. They bring the latest food technologies to life in their own food grade processing plant. Their passion is to make better foods and to be an incubator of innovation. Their customers value their gains in sustainability, cost effectiveness and speed to market.
AM Pharma
Series E in 2014
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.
Sapiens Steering Brain Stimulation
Series C in 2013
Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.
Pharmaline
Private Equity Round in 2012
Pharmaline is a young, innovative, semi-industrial compounding pharmacy, based in Oldenzaal. In 2009 they started with 30 employees; at this time that there are over 140. Their highly qualified company has been set up according to the latest GMP guidelines. They offer about 700 pharmacists in the Netherlands a rational and comprehensive range of pharmaceutical solutions, service and advice. Standardization, rationalization, knowledge and expertise are central, increasing the quality of care while reducing healthcare costs. Their mission is short and sweet: "Care for Saving lives and costs. Pharmaline offers the full package pharmacy compounding that is common in community pharmacies. This applies both to stock preparations as ad hoc preparations at the patient level in the form of creams, ointments, tablets, capsules, drops, liquids, suspensions, and injectabilia (injections, infusions, cassettes). You do not need to look where certain products are available; with us you can find all your pharmacy preparations! Their experienced pharmacists are daily available to advise you on rationality, pharmacotherapy, production engineering, application engineering and legislation. Of course they also have the most modern equipment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.